PR Newswire · Press release
What's Next for Tenax Therapeutics, Inc. Shareholders After 89.77% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
Original release from PR Newswire
As distributed by PR Newswire, unedited.
Complaint alleges Tenax Therapeutics, Inc. misled investors between November 13, 2023 and August 7, 2026; investors may seek lead plaintiff role by December 28, 2026
LOS ANGELES, Nov. 10, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class action lawsuit covers investors who bought Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026. The Tenax Therapeutics, Inc. case, Katz v. Tenax Therapeutics, Inc. et al., was filed on October 26, 2026 in the U.S. District Court North Carolina Middle District (Case No. 1:26-cv-01264).
Investors who suffered losses on Tenax Therapeutics, Inc. investments can submit their Tenax Therapeutics, Inc. loss information here before the December 28, 2026 lead plaintiff deadline.
Key dates in the Tenax Therapeutics, Inc. case
- Class period: November 13, 2023 to August 7, 2026
- Complaint filed: October 26, 2026
- Lead plaintiff deadline: December 28, 2026
What happened?
On August 10, 2026, Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial. The press release stated that TNX-103 "did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score."
On this news, Tenax's stock fell $12.06 per share, or 89.77%, to close at $1.38 per share on August 10, 2026, thereby injuring investors.
What is the Tenax Therapeutics, Inc. lawsuit about?
The Tenax Therapeutics, Inc. securities lawsuit alleges that, between November 13, 2023 and August 7, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Tenax Therapeutics, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) TNX-103 was less effective than Defendants had led investors to believe; (2) accordingly, TNX-103's overall clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' positive statements about Tenax Therapeutics, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
"The complaint against Tenax Therapeutics, Inc. alleges, among other things, that the Company failed to disclose that TNX-103 was less effective than Defendants had led investors to believe. For investors who purchased during the class period, the December 28, 2026 lead plaintiff deadline is the first significant deadline to keep in mind," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.
What's the next step?
Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist Tenax Therapeutics, Inc. investors in potentially pursuing claims to recover their losses.
If you wish to serve as lead plaintiff in the Tenax Therapeutics, Inc. class action, you must move the Court no later than December 28, 2026. To learn more about your rights, visit the Tenax Therapeutics, Inc. case page, email shareholders@glancylaw.com, or call 310-201-9150 (toll-free: 888-773-9224).
You may retain counsel of your choice. If you bought Tenax Therapeutics, Inc. securities during the class period, you may take no action and remain an absent class member. No class has been certified yet in the Tenax Therapeutics, Inc. case.
Frequently Asked Questions
Who is eligible? Investors who purchased or otherwise acquired Tenax Therapeutics, Inc. securities between November 13, 2023 and August 7, 2026 and suffered losses may be members of the proposed class in the Tenax Therapeutics, Inc. shareholder lawsuit. Any class member may ask the court to appoint them lead plaintiff by December 28, 2026.
What is a lead plaintiff? In the Tenax Therapeutics, Inc. class action, the lead plaintiff is the investor, or group of investors, that the court appoints to represent all class members and oversee the case. Under the Private Securities Litigation Reform Act, courts generally presume the movant with the largest financial interest is the most adequate lead plaintiff.
Do I have to be lead plaintiff to recover? No. A Tenax Therapeutics, Inc. investor's ability to share in any future recovery does not depend on serving as lead plaintiff. Tenax Therapeutics, Inc. investors may take no action and remain absent class members.
What is the deadline? Motions to serve as lead plaintiff in the Tenax Therapeutics, Inc. class action must be filed by December 28, 2026.
Does it cost anything to contact Glancy or participate in this action? Glancy represents Tenax Therapeutics, Inc. investors on a contingency fee basis, so investors pay no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.
Can I choose my own lawyer? Yes. Tenax Therapeutics, Inc. investors may retain counsel of their choice.
Why work with Glancy on the Tenax Therapeutics, Inc. lawsuit? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Tenax Therapeutics, Inc. lawsuit. Prior results do not guarantee a similar outcome.
About Glancy Prongay Wolke & Rotter LLP
Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.
Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
Prior results do not guarantee a similar outcome.
Related links
- Tenax Therapeutics, Inc. case page, Glancy Prongay Wolke & Rotter LLP
- Complaint: Katz v. Tenax Therapeutics, Inc. et al., U.S. District Court North Carolina Middle District
- Tenax Press Release
- Tenax Therapeutics, Inc. SEC filings index, EDGAR
- Glancy Prongay Wolke & Rotter LLP
Contact
Charles H. Linehan
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 | Toll-free: 888-773-9224
www.glancylaw.com
Follow Glancy on LinkedIn, X, or Facebook.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View original content to download multimedia:https://www.prnewswire.com/news-releases/whats-next-for-tenax-therapeutics-inc-shareholders-after-89-77-stock-drop-glancy-prongay-wolke--rotter-llp-explains-securities-fraud-class-action-lead-plaintiff-deadline-302935172.html
SOURCE Glancy Prongay Wolke & Rotter LLP
